Overview

MetrioPharm Develope Pipeline

News

Last Patient Out: MetrioPharm Completes Clinical Phase II Trial in COVID-19 - 2022-Jul-29

The objective of the study is to determine whether treatment with MetrioPharm’s lead compound MP1032 can slow the spread of the virus and alleviate COVID-19 symptoms in recently hospitalized patients.In preclinical trials the compound had shown both antiviral and anti-inflammatory properties.

» more

Investor Relations

Investor Relations News QII 2022 - 2022-Jun-30

16th Annual General Meeting of MetrioPharm AG, Bio-Europe Spring in Basel, BIO International Convention in San Diego, Company Calendar, London-Paris in 24 hours, MetrioPharm AG informs

» more